Applicant : Graeme Semple, et al. Serial No. : 10/533,799 Filed : May 4, 2005 Page : 2 of 29

Amendments to the Claims:

Please cancel claim 21 and add new claim 29. Please amend claims 3-12, 21, 26, and 27 as shown herein. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

(Previously presented) A compound of Formula (I):

$$R_1$$
 R_3 R_3

wherein:

R, is C_{1,8} alkyl, C_{2,6} cyclosikyl or C_{1,6} haloalkyl, wherein the C_{1,8} alkyl, C_{3,6} cyclosikyl and C_{1,6} haloalkyl groups are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of C_{1,6} acyl, C_{1,6} acyloxy, C_{2,6} alkenyl, C_{1,6} alkylex alkylex alkylex constant (C_{2,6} alkylex)lyl, C_{1,6} alkylex al

R₃, R₃ and R₄ are each independently selected from the group consisting of H₂, C₁, eacy, C₁, eacylexy, C₂, ealkenyl, C₁, ealkoxy, C₁, ealklyd, C₁, ealklytentroxamido, C₂, ealkynyl, C₁, ealkylumlionyl, C₁, ealkylumlionyl, C₂, ealkylumlion, C₁, ealkylumlion, C₁, ealkylumlion, C₂, ealkylumlion, C₃, ealkylumlion, C₂, ealkylumlion, C₃, ealkylumlion, C₃, ealkylumlion, C₃, ealkylumlion, C₄, ealkylumlion, C₃, ealkylumlion, C₄, ealkylumlion, C₃, ealkylumlion, C₄, ealkylumlion,

Rs is H or CLs alkyl; or

Applicant : Graeme Semple, et al. Serial No. : 10/533,799 Filed : May 4, 2005 Page : 3 of 29

> a pharmaceutically acceptable salt, solvate or hydrate thereof; provided that:

- a) when R_5 is ethyl, and R_2 , R_3 and R_4 are H then R_1 is not methyl or triphenylmethyl:
 - b) when Rs is n-pentyl, and Rs, Rs and Rs are H then Rs is not n-butyl;
- c) when Rs is methyl, and Rs, R3 and R4 are H then R1 is not pyrrolidin-1-
- ylmethyl, 3-tert-butyl-2-hydroxy-5-methyl-benzyl, methyl, or dimethylaminomethyl; d) when R₂ is methyl, R₂ is carbomethoxy and R₃ and R₄ are both H then R₁ is
- not methyl;

 e) when R₂, R₄, R₄ and R₅ are all H then R₁ is not 2-amino-2-carboxy-ethyl,
- pyrrolidin-1-vlmethyl, isopropyl, methyl, benzyl, n-butyl, or carboxymethyl; and
 - when R₃, R₄, and R₅ are all H and R₃ is methoxy then R₁ is not methyl.

2. (Previously presented) A compound according to claim 1 wherein:

R, is $C_{2,6}$ cycloality for $C_{1,6}$ halonity, where each $C_{2,6}$ cycloality of $C_{1,6}$ halonity group is optionally substituted with 1, 2, 3, or 4 substitutents selected form the group consisting of $C_{1,6}$ acyl, $C_{1,6}$ and $C_{1,6}$ and $C_{1,6}$ and $C_{1,6}$ alkyhulfinyl, $C_{1,6}$ fallolityl, $C_{1,6}$ halonityl, $C_{1,6}$ halonityl,

 R_s , R_s and R_s are each independently selected from the group consisting of H_s (C_s acyloxy, C_{sd} allakenyl, C_{sd} allakoy, C_{sd} allay, C_{sd} ally clarebroamido, C_{sd} ally sulfingly, C_{sd} allay sulfingly, C_{sd} ally sulfingly, C_{sd} ally sulfingly, C_{sd} ally sulfingly, C_{sd} alloy sulfingly, C_{sd} allay lamino, C_{sd} dially samino, carbo C_{sd} allowy, carboxy, cyano, C_{sd} eyeloally, C_{sd} dially (arboxamido, halogen, C_{sd} haloalloxy, C_{sd} alloallikoy, C_{sd} alloallikoy,

 $R_{\scriptscriptstyle 3}$ is H or $C_{1:4}$ alkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

 (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₁ is C_{1,6} alkyl.

Applicant : Graeme Semple, et al. Serial No. : 10/533,799 Filed : May 4, 2005 Page : 4 of 29

 (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₁ is H.

- 5. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₂, R₃ and R₄ are each independently H or halogen.
- 6. (Currently amended) The compound according to claim 1, or a pharmaccutically acceptable salt, solvate or hydrate thereof, wherein R2, R3 and R4 are each independently H or F.
- 7. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable sall.
 3. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable sall.
 substituents selected from the group consisting of C_{2,4} alkenyl, C_{1,4} alkenyl, C_{1,4} alkynyl, C_{1,4} alkylsulfinyl, C_{1,4} alkylsulfinyl, C_{1,4} alkylsulfinyl, C_{1,4} alkylsulfinyl, C_{1,4} alkylsulfinyl, C_{1,4} alkylsulfinyl, C_{1,4} alkoalkylsulfinyl, C_{1,4} alkoalkylsulfinyl, C_{1,4} haloalkylsulfinyl, C_{1,4} haloalkylsu
- 8. (Currently amended) The compound according to claim 1,or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R; is selected from the group consisting of 2-bulyl, 3pentlyl, 1-propyl, 1-buryl, 1-butyl, 4-Methyl-pentlyl, 3-methyl-bulyl, 1,3-dimethyl-bulyl, 3,3dimethyl-bulyl, 1-bepyl, ctulyl, 2,2-dimethyl-propyl, and 1-pentlyl.
- 9. (Currently amended) The compound according to claim 1_or a pharmacoutically acceptable salt, solvate or bydrate thereof, wherein R, is selected from the group consisting of 3-methoxybenzyl, 4-methoxy-benzyl, 4-methoxy-phenyl ethyl, 3-methoxy-phenyl ethyl, 3,5-difluorobenzyl, and benzhydryl.
- 10. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable asis, solvate or hydrate thereof, wherein R; is selected from the group consisting of 3-isonrocov procov), tetrahydro-furan-2-vimethyl. 2-methoxy-ethyl. 2-chivalifanyl-ethyl. 3-

Applicant: Graeme Semple, et al. Attorney's Docket No.: 22578-0003US1 / 32.US2.PCT

Serial No.: 10/533,799 Filed: May 4, 2005 Page: 5 of 29

> hydroxy-propyl, allyl, cyclopropylmethyl, but-2-ynyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-1hydroxymethyl-ethyl, 2-ethoxy-ethyl, and 1,2-dimethyl-propyl.

(Currently amended) The compound according to claim 1, or a pharmaceutically
acceptable salt, solvate or hydrate thereof, wherein R₁ is selected from the group consisting of
evelopentyl, evelopercyl, and evelopentyl.

(Currently amended) The compound according to claim 1 selected from the group consisting
 of:

1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;

1-(2'-Butyl)-1H-henzotriazole-5-carboxylic acid:

I-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;

1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid

1-Propyl-1H-benzotriazole-5-carboxylic acid;

1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;

1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid;

1-(Tetrahydro-furan-2'-ylmethyl)-1H-benzotriazole-5-carboxylic acid;

1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;

1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid; 1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;

1-[2'-(4"-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;

1-[2'-(3''-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;

1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;

1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-t-Butyl-1H-benzotriazole-5-carboxylic acid;

1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;

1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;

1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid; 1-Heptyl-1H-benzotriazole-5-carboxylic acid:

1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;

Applicant : Graeme Semple, et al. Serial No. : 10/533,799 Filed : May 4, 2005

Page : 6 of 29

1-(2'-Hvdroxy-1'-hvdroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid:

1-Ethyl-1H-benzotriazole-5-carboxylic acid:

1-Pentyl-1H-benzotriazole-5-carboxylic acid:

1-(2'.2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid:

1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid:

1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;

1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;

1-Allyl-1H-benzotriazole-5-carboxylic acid;

1-Butyl-1H-benzotriazole-5-carboxylic acid;

1-(Cvclopropvlmethyl)-1H-benzotriazole-5-carboxvlic acid:

(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;

1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and

1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

(Previously presented) A pharmaceutical composition comprising a compound according to

wherein:

Formula (I):

R₄ is H, C₁₄ alkyl, C₂₄ cycloalkyl or C₁₄ haloalkyl, wherein each C₁₄ alkyl, C₂₅ cycloalkyl or C₁₅ haloalkyl group is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁₄ asylor, C₁₄ alkylor, C₂₄ alkylor, C₁₄ alkon, C₁₅ alkylor, C₁₄ al

Applicant: Graeme Semple, et al. Attorney's Docket No.: 22578-0003US1 / 32.US2 PCT

Serial No.: 10/533,799 Filed: May 4, 2005 Page: 7 of 29

 R_0 , R_0 and R_4 are each independently selected from the group consisting of H, $C_{1,4}$ acyl, $C_{1,4}$ acyl, $C_{1,4}$ allory), $C_{1,4}$ allority, $C_{1,4}$ allority, and $C_{1,4}$ allority, $C_{1,4}$ allority, and $C_{1,4}$ allority, $C_{1,4}$ allority, $C_{1,4}$ allority, and $C_{1,4}$ allority, $C_{1,4}$ allority, and $C_{1,4}$ allority, $C_{1,4}$ allority, and $C_{1,4}$ allority, allority, and $C_{1,4}$ allority,

Re is H or Crealkyl: or

a pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with a pharmaceutically acceptable carrier.

14. (Original) A pharmaceutical composition according to claim 13 further comprising an agent selected from the group consisting of α-glucosidase inhibitor, aldone reductase inhibitor, biguardide, HMG-GoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and this rodifications.

15-19. (Canceled)

20. (Currently amended) A method of treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atheroselerosis, coronary heart disease, insulin resistance and type 2 diabetes comprising administering to an individual in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.

21-25. (Canceled)

26. (Currently amended) A method of treatment of a metabolic-related disorder selected from the group consisting of deslipidemia, atheroselerosis, coronary heart disease, insulin resistance and type 2 diabetes comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or brefate thereof.

Applicant : Graeme Semple, et al. Serial No. : 10/533,799 Filed : May 4, 2005

Page : 8 of 29

27. (Currently Amended)

A method according to claim 26 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, ceronary heart disease.

28. (Previously presented) The pharmaceutical composition according to claim 13 wherein said compound is selected from the group consisting of:

1-Isopropyl-1H-benzotriazole-5-carboxylic acid;

insulin resistance and type 2 diabetes.

1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;

1-(2'-Butyl)-1H-benzotriazole-5-carboxylic acid;

1-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;

1-Benzyl-1H-benzotriazole-5-carboxylic acid:

1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid

1-Propyl-1H-benzotriazole-5-carboxylic acid:

1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;

1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid:

1-(Tetrahydro-furan-2'-vlmethyl)-1H-benzotriazole-5-carboxylic acid:

1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;

1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;

1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid; 1-[2'-(4''-Methoxy-phenyl)-ethylaminol-1H-benzotriazole-5-carboxylic acid;

1-[2'-(3"-Methoxy-phenyl)-ethylaminol-1H-benzotriazole-5-carboxylic acid:

1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;

1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-t-Butyl-1H-benzotriazole-5-carboxylic acid;

1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;

1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;

1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;

1-Heptyl-1H-benzotriazole-5-carboxylic acid;

1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-(2'-Hydroxy-1'-hydroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid;

Applicant : Graeme Semple, et al. Serial No. : 10/533,799

Filed : May 4, 2005 Page : 9 of 29

1-Ethyl-1H-benzotriazole-5-carboxylic acid:

1-Pentyl-1H-benzotriazole-5-carboxylic acid:

1-(2',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;

1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;

1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;

1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;

1-Allyl-1H-benzotriazole-5-carboxylic acid;

1-Butyl-1H-benzotriazole-5-carboxylic acid;

1-(Cyclopropylmethyl)-1H-benzotriazole-5-carboxylic acid;

1-(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;

1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and

1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

 (New) A method according to claim 26 wherein said metabolic-related disorder is atherosclerosis.